ACAD:NGS-ACADIA Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 16.25

Change

0.00 (0.00)%

Market Cap

USD 3.24B

Volume

1.67M

Analyst Target

USD 59.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of medicines to address unmet medical needs in central nervous system disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.53 (+0.54%)

USD 120.95B
REGN Regeneron Pharmaceuticals Inc

+5.99 (+0.57%)

USD 115.81B
MRNA Moderna Inc

-2.80 (-2.36%)

USD 45.51B
ALNY Alnylam Pharmaceuticals Inc

+0.32 (+0.13%)

USD 28.20B
ARGX argenx NV ADR

+4.18 (+0.97%)

USD 26.78B
BNTX BioNTech SE

-1.53 (-1.90%)

USD 20.40B
GMAB Genmab AS

-0.28 (-1.11%)

USD 16.65B
BMRN Biomarin Pharmaceutical Inc

-0.20 (-0.24%)

USD 15.98B
RPRX Royalty Pharma Plc

-0.18 (-0.68%)

USD 15.75B
BGNE BeiGene Ltd

+2.22 (+1.56%)

USD 15.73B

ETFs Containing ACAD

IBRN iShares Trust - iShares N.. 4.30 % 0.00 %

+0.17 (+0.73%)

USD 3.84M
BBP Virtus LifeSci Biotech Pr.. 1.73 % 0.79 %

+0.31 (+0.73%)

USD 0.02B
CHEP 0.00 % 1.12 %

N/A

N/A
SIZ 0.00 % 1.71 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -48.10% 23% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -48.10% 23% F 13% F
Trailing 12 Months  
Capital Gain -32.15% 48% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.15% 48% F 29% F
Trailing 5 Years  
Capital Gain -39.64% 62% D 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -39.64% 62% D 30% F
Average Annual (5 Year Horizon)  
Capital Gain -3.43% 54% F 36% F
Dividend Return -3.43% 54% F 34% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 43.93% 64% D 39% F
Risk Adjusted Return -7.80% 51% F 36% F
Market Capitalization 3.24B 92% A 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 6.54 22% 17%
Price / Cash Flow Ratio 160.75 1% 1%
Price/Free Cash Flow Ratio -36.01 97% 93%
Management Effectiveness  
Return on Equity -0.41% 95% 58%
Return on Invested Capital -20.10% 79% 34%
Return on Assets -0.38% 96% 59%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.